Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Text-based Reminders to Promote COVID-19 Vaccinations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04801524
Recruitment Status : Enrolling by invitation
First Posted : March 17, 2021
Last Update Posted : March 24, 2021
Sponsor:
Collaborator:
Carnegie Mellon University
Information provided by (Responsible Party):
Daniel M. Croymans, MD, MBA, MS, University of California, Los Angeles

Brief Summary:
This study investigates whether and which type of text-based reminders affect the take-up of the COVID-19 vaccine.

Condition or disease Intervention/treatment Phase
Covid19, Vaccines Behavioral: Self-benefit Behavioral: Prosocial-benefit Behavioral: Early access Behavioral: Fresh start Not Applicable

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Health Services Research
Official Title: Text-based Reminders to Promote COVID-19 Vaccinations
Actual Study Start Date : February 7, 2021
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : January 1, 2022

Arm Intervention/treatment
No Intervention: Holdout Arm
In the Holdout arm: patients will not receive a second text message about COVID-vaccine.
Experimental: Self-benefit sub-arm
In the Self-benefit sub-arm, participants will be reminded that the vaccine helps protect themselves from COVID.
Behavioral: Self-benefit
Participants will be reminded that the vaccine helps protect themselves from COVID.

Experimental: Prosocial-benefit sub-arm
In the Prosocial-benefit sub-arm, participants will be reminded that the vaccine helps protect their family, friends, and community from COVID.
Behavioral: Prosocial-benefit
Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID

Experimental: Early-access and self-benefit sub-arm
In the Early access + self-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect themselves from COVID.
Behavioral: Self-benefit
Participants will be reminded that the vaccine helps protect themselves from COVID.

Behavioral: Early access
Participants will be reminded that they have early access to COVID-19 vaccine.

Experimental: Early-access and prosocial-benefit sub-arm
In the Early access + prosocial-benefit sub-arm, participants will be reminded that they have early access to COVID-19 vaccine and should take the opportunity to protect their family, friends, community from COVID.
Behavioral: Prosocial-benefit
Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID

Behavioral: Early access
Participants will be reminded that they have early access to COVID-19 vaccine.

Experimental: Fresh start and self-benefit sub-arm
In the Fresh start + self-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect themselves from COVID and chart a new path forward.
Behavioral: Self-benefit
Participants will be reminded that the vaccine helps protect themselves from COVID.

Behavioral: Fresh start
Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.

Experimental: Fresh start and prosocial-benefit sub-arm
In the Early access + prosocial-benefit sub-arm, participants will be reminded that the vaccine offers the promise of a fresh start and they should take the opportunity to protect their family, friends, community from COVID and help our nation chart a new path forward.
Behavioral: Prosocial-benefit
Participants will be reminded that the vaccine helps protect their family, friends, and community from COVID

Behavioral: Fresh start
Participants will be reminded that the vaccine offers the promise of a fresh start and chart a new path forward.




Primary Outcome Measures :
  1. First COVID-19 Vaccine Appointment Scheduled at UCLA Health [ Time Frame: 6 days ]
    Whether patients schedule their vaccination appointment at UCLA Health within 6 days of receiving the second text message (including the day of text message). Specifically, if t=the date of the second text message (for the holdout arm, this refers to the date they would have received the text message had they not been assigned to the holdout arm), we will track vaccination appointments made by the end of t+5. While most people just make one appointment, a small percentage update their appointment time. We will have access to the latest few first-dose appointments people schedule by the time of data extraction.


Secondary Outcome Measures :
  1. First COVID-19 Vaccine obtained at UCLA Health [ Time Frame: 1 months from text message ]
    Whether patients get the first dose of COVID-19 vaccine at UCLA Health [time frame: 1 months from text message]

  2. Time of obtaining the first COVID-19 vaccine at UCLA Health [ Time Frame: 1 months from text message ]
    The date when patients obtain the first dose of COVID-19 vaccine at UCLA Health [time frame: 1 months from text message]

  3. First COVID-19 Vaccine obtained at UCLA Health or any organization reporting to CAIR [ Time Frame: 2 months from text message ]
    Whether patients obtain the first dose of COVID-19 vaccine at UCLA Health or another location reporting to the California Immunization Registry (CAIR). [time frame: 2 months from text message]

  4. Time of obtaining the first COVID-19 at UCLA Health or another location reporting to CAIR [ Time Frame: 2 months from text message ]
    The date when patients obtain the first dose of COVID-19 vaccine at UCLA Health or another location reporting to the California Immunization Registry (CAIR) [time frame: 2 months from text message]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

All patients who satisfy the following criteria will be eligible to be included in our study:

  • They have a mobile phone number or SMS capable phone number in UCLA Health's database
  • They are eligible for receiving the COVID-19 vaccine at UCLA Health
  • They have not already scheduled an appointment the day before the scheduled time of the text message
  • They are at or above 18 years old

Exclusion Criteria: Patients who already scheduled an appointment or obtained a COVID vaccine (at our collaborating health system or as documented in the California Immunization Registry (CAIR) https://cairweb.org) by the time our text message is sent will be excluded from the analysis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04801524


Locations
Layout table for location information
United States, California
UCLA Health Department of Medicine, Quality Office
Westwood, California, United States, 90095
Sponsors and Collaborators
University of California, Los Angeles
Carnegie Mellon University
Publications:
Layout table for additonal information
Responsible Party: Daniel M. Croymans, MD, MBA, MS, Medical Director of Quality, Dept of Medicine, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT04801524    
Other Study ID Numbers: IRB#21-000268 (2)
First Posted: March 17, 2021    Key Record Dates
Last Update Posted: March 24, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Daniel M. Croymans, MD, MBA, MS, University of California, Los Angeles:
COVID19
Vaccines
Text-messages
Patient Outreach
Behavioral Science